# DESCRIPTION

## FIELD OF THE INVENTION

- relate EGFR gene mutation to cancer therapy resistance

## BACKGROUND OF THE INVENTION

- motivate EGFR as cancer therapy target

## SUMMARY OF THE INVENTION

- introduce EGFR mutant detection method
- describe PCR primer for mutant detection
- outline method for detecting mutant EGFR gene
- summarize kit for mutant detection

## DETAILED DESCRIPTION OF THE INVENTION

- define abbreviations and accession numbers
- describe EGFR numbering systems and mutations
- define terms: tumor, cancer, nucleic acid, polynucleotide, oligonucleotide
- describe nucleotide sequences and modifications
- describe bases: natural and modified
- describe linkages between nucleotides: natural and modified
- define complementarity and hybridization
- define liberate and hybridize
- define fragment
- define cleaving means
- describe complementary DNA
- outline methods for detecting EGFR T790M mutation
- describe diagnostic kit for detecting mutant EGFR T790M
- illustrate primer sequences
- describe synthesis of polynucleotides
- outline amplification process
- describe detection of amplification products
- outline alternative methods of amplification
- describe detection of predetermined sequence variations

### Designing an Allele Specific Oligonucleotide (ASO) Probe

- define ASO probe
- design requirements of ASO probe
- limitations of conventional ASO probes
- alternative methods for large scale analysis
- embodiments of the invention for diagnosing cancer

## EXAMPLES

### Materials and Methods

- procure tissue specimens
- analyze EGFR and KRAS mutations
- perform RT-PCR and functional analyses

### Example 1

- confirm EGFR T790M mutation using allele-specific oligonucleotide PCR

### Clonal Origin of the EGFR T790M Mutation

- demonstrate clonal origin of EGFR T790M mutation using PCR and tumor microdissection

### Assay for the EGFR T790M Mutation in Genomic DNA

- detect EGFR T790M mutation using PCR-RFLP and fluorescent capillary electrophoresis

### Case Reports

- present case histories of patients with secondary EGFR mutations

### Example 5

- identify EGFR mutations in patients' tumors
- analyze EGFR mutations in tumor samples from three patients
- detect secondary missense mutation in EGFR kinase domain
- analyze EGFR mutations in additional patients and cell lines
- rule out KRAS mutations as cause of drug resistance
- develop PCR-RFLP assay to detect T790M mutation
- analyze biochemical properties of EGFR mutants
- test resistance of NSCLC cell line to gefitinib or erlotinib

